Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro

Journal of Biomedical Materials Research - Part A

Volumn 89, Issue 1, 2009, Pages 46-56

  Faucheux, C ^a,b   Verron, E ^a,b   Soueidan, A ^a,b   Josse, S ^c   Arshad, M D ^a,b   Janvier, P ^c   Pilet, P ^a,b   Bouler, J M ^a,b   Bujoli, B ^c   Guicheux, J ^a,b  

^a Universite de Nantes   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CNRS   (France)

Author keywords

Bisphosphonate; Calcium phosphate biomaterial; Drug delivery system; Osteoblast

Indexed keywords

ALKALINE PHOSPHATASE ACTIVITIES; BIOLOGICAL PROPERTIES; BISPHOSPHONATE; BISPHOSPHONATES; BONE CELLS; BONE TISSUES; CALCIUM DEFICIENT APATITES; COATING PROCESS; CONTROLLED RELEASE; DRUG DELIVERY SYSTEM; F ACTINS; IN-VITRO; IN-VIVO; MAS-NMR; OSTEOBLASTIC CELLS; VITRONECTIN;

BIOLOGICAL MATERIALS; BIOMATERIALS; BONE; CALCIUM; CALCIUM ALLOYS; CELL CULTURE; DRUG DELIVERY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOBLASTS; PHOSPHATE MINERALS;

CALCIUM PHOSPHATE;

ANIMALS; APATITES; BIOCOMPATIBLE MATERIALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM PHOSPHATES; CELLS, CULTURED; DIPHOSPHONATES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; IMIDAZOLES; MATERIALS TESTING; OSTEOBLASTS; OSTEOCLASTS; RABBITS;

EID: 62249156240     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31989     Document Type: Article

References (43)

1. Gallagher A, Chambers TJ, Tobias JH. The estrogen antagonist ICI 182, 780 reduces cancellous bone volume in female rats. Endocrinology 1993;133:2787-2791.
2. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153-164.
3. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-1514.
4. Raisz LG, Rodan GA. Pathogenesis of osteoporosis. Endocrinol Metab Clin North Am 2003;32:15-24.
5. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304-313.
6. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212:901-903.
7. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-2658.
8. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain 1998;78:157-169.
9. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(12 Suppl):2961-2978.
10. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
11. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-4796.
12. Green JR, Clezardin P Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002;25(6, Suppl 1):S3-S9.
13. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999;274:34967-34973.
14. Daculsi G, Bouler JM, LeGeros RZ. Adaptive crystal formation in normal and pathological calcifications in synthetic calcium phosphate and related biomaterials. Int Rev Cytol 1997;172:129-191.
15. LeGeros RZ. Properties of osteoconductive biomaterials: Calcium phosphates. Clin Orthop 2002;395:81-98.
16. Obadia L, Amador G, Daculsi G, Bouler JM. Calcium-deficient apatite: Influence of granule size and consolidation mode on release and in vitro activity of vancomycin. Biomaterials 2003;24:1265-1270.
17. Magne D, Faucheux C, Daculsi G, Guicheux J. Calcium phosphate ceramics as carrier for bone therapeutic agents. Drug Discov Today 2002;7:928-931.
18. Cavagna R, Daculsi G, Bouler JM. Macroporous calcium phosphate ceramic: A prospective study of 106 cases in lumbar spinal fusion. J Long Term Eff Med Implants 1999;9:403-412.
19. Josse S, Faucheux C, Grimandi G, Massiot A, Alonso B, Janvier P, Pilet P, Gauthier O, Daculsi G, Guicheux J, Bujoli B, Bouler JM. An innovative strategy for local treatment of bone resorption and prevention of osteoporotic fractures. Adv Mater 2004;16:1423-1427.
20. Denissen H, Van Beek E, Martinetti R, Klein C, Van der Zee E, Ravaglioli A. Net shaped hydroxyapatite implants for release of agents modulating periodontal-like tissues. J Periodont Res 1997;32:40-46.
21. Josse S, Faucheux C, Soueidan A, Grimandi G, Massiot D, Alonso B, Janvier P, Laib S, Pilet P, Gauthier O, Daculsi G, Guicheux J, Bujoli B, Bouler J-M. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005;26:2073-2080.
22. Obadia L, Rouillon T, Bujoli B, Daculsi G, Bouler JM. Calcium-deficient apatite synthesized by ammonia hydrolysis of dicalcium phosphate dihydrate: Influence of temperature, time, and pressure. J Biomed Mater Res B Appl Biomater 2007;80:32-42.
23. Gauthier O, Bouler JM, Weiss P, Bosco J, Aguado E, Daculsi G. Short-term effects of mineral particle sizes on cellular degradation activity after implantation of injectable calcium phosphate biomaterials and the consequences for bone substitution. Bone 1999;25(2 Suppl):71S-74S.
24. Bouler JM, LeGeros RZ, Daculsi G. Biphasic calcium phosphates: Influence of three synthesis parameters on the HA/β-TCP ratio. J Biomed Mater Res 2000;51:680-684.
25. Gauthier O, Boix D, Grimandi G, Aguado E, Bouler JM, Weiss P, Daculsi G. A new injectable calcium phosphate bio- material for immediate bone filling of extraction sockets: A preliminary study in dogs. J Periodontol 1999;70:375-383.
26. Guicheux J, Heymann D, Rousselle AV, Gouin F, Pilet P, Yamada S, Daculsi G. Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I: An in vitro study. Bone 1998;22:25-31.
27. Lakkakorpi PT, Horton MA, Helfrich MH, Karhukorpi EK, Vaananen HK. Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface. J Cell Biol 1991;115:1179-1186.
28. Faucheux C, Horton MA, Price JS. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: Evidence for parathyroid hormone-related protein and receptor activator of NF-κB-dependent effects on osteoclast formation in regenerating mammalian bone. J Bone Miner Res 2002;17:455-464.
29. Grimandi G, Soueidan A, Anjrini AA, Badran Z, Pilet P, Daculsi G, Faucheux C, Bouler JM, Guicheux J. Quantitative and reliable in vitro method combining scanning electron microscopy and image analysis for the screening of osteotropic modulators. Microsc Res Tech 2006;69:606-612.
30. Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G, Caverzasio J. Activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003;18:2060-2068.
31. Vinatier C, Magne D, Weiss P, Trojani C, Rochet N, Carle GF, Vignes-Colombeix C, Chadjichristos C, Galera P, Daculsi G, Guicheux J. A silanized hydroxypropyl methylcellulose hydrogel for the three-dimensional culture of chondrocytes. Biomaterials 2005;26:6643-6651.
32. Magne D, Bluteau G, Faucheux C, Palmer G, Vignes-Colombeix C, Pilet P, Rouillon T, Caverzasio J, Weiss P, Daculsi G, Guicheux J. Phosphate is a specific signal for ATDC5 chondrocyte maturation and apoptosis-associated mineralization: Possible implication of apoptosis in the regulation of endochondral ossification. J Bone Miner Res 2003;18:1430-1442.
33. Schmidt-Rohr K, Spiess HW. Multidimensional Solid State NMR and Polymers. New York: Academic Press; 1994.
34. Schilling AF, Linhart W, Filke S, Gebauer M, Schinke T, Rueger JM, Amling M. Resorbability of bone substitute biomaterials by human osteoclasts. Biomaterials 2004;25:3963-3972.
35. Burchardt H. The biology of bone graft repair. Clin Orthop 1983;174:28-42.
36. Papapoulos SE. Who will benefit from antiresorptive treatment (bisphosphonates)? Best Pract Res Clin Rheumatol 2005;19:965-973.
37. Orcel P Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Joint Bone Spine 2005;72:461-465.
38. Bourgeois B, Laboux O, Obadia L, Gauthier O, Betti E, Aguado E, Daculsi G, Bouler JM. Calcium-deficient apatite: A first in vivo study concerning bone ingrowth. J Biomed Mater Res A 2003;65:402-408.
39. Widler L, Jaeggi KA, Glatt M, Muller K, Bachmann R, Bisping M, Born AR, Cortesi R, Guiglia G, Jeker H, Klein R, Ramsier U, Schmid J, Schreiber G, Seltenmeyer Y, Green JR. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002;45:3721-3738.
40. Roussiere H, Montavon G, Laib S, Janvier P, Alonso B, Fayon F, Petit M, Massiot D, Bouler JM, Bujoli B. Hybrid materials applied to biotechnologies: Coating of calcium phosphates for the design of implants active against bone resorption. J Mater Chem 2005;15:3869-3875.
41. Heymann D, Guicheux J, Gouin F, Passuti N, Daculsi G. Cytokines, growth factors and osteoclasts. Cytokine 1998;10:155-168.
42. Schindeler A, Little DG. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 2005;338:710-716.
43. Chaplet M, Detry C, Deroanne C, Fisher LW, Castronovo V, Bellahcene A. Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J 2004;384 (Part 3):591-598.